论文部分内容阅读
目的:探讨溶酶体组织蛋白酶L(cathepsinL)与扩张型心肌病发病的关系。方法:收集因终末期扩张型心肌病行心脏移植术的受体标本20例为心肌病组及脑死亡3h内排除心脏疾患的心脏标本5例为正常对照组,通过免疫组化及RT-PCR等方法半定量分析心肌组织中cathepsinL蛋白阳性颗粒及mRNA表达水平,并对cathepsinLmRNA表达水平的动态变化与心功能(EF值)的相关性进行分析。结果:心肌病组心肌组织中cathepsinL蛋白阳性颗粒及mRNA表达水平均明显高于对照组,均有极显著差异(P<0.01);心肌组织cathepsinLmRNA表达水平的变化与EF值的变化呈显著负相关(r=-0.544,P<0.05)。结论:cathepsinL参与了扩张型心肌病的发生发展。
Objective: To investigate the relationship between lysosomal cathepsin L and dilated cardiomyopathy. Methods: Twenty patients with cardiomyopathy undergoing cardiological transplantation for end-stage dilated cardiomyopathy were selected as cardiomyopathy group and 5 cases of heart disease excluding heart disease within 3 hours after brain death as normal control group. Immunohistochemistry and RT-PCR Methods The mRNA and protein levels of cathepsin L in myocardial tissue were semi-quantitatively analyzed. The correlation between the dynamic changes of cathepsin L mRNA expression and cardiac function (EF) was analyzed. Results: The expression of cathepsin L protein in myocardial tissue of cardiomyopathy group was significantly higher than that of the control group (P <0.01). The changes of cathepsin L mRNA expression in myocardial tissue were negatively correlated with the change of EF value (r = -0.544, P <0.05). Conclusions: cathepsinL is involved in the development of dilated cardiomyopathy.